These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 23885284)

  • 1. Commercial Opportunities and Ethical Pitfalls in Personalized Medicine: A Myriad of Reasons to Revisit the Myriad Genetics Saga.
    So D; Joly Y
    Curr Pharmacogenomics Person Med; 2013 Jun; 11(2):98-109. PubMed ID: 23885284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The History of Patenting Genetic Material.
    Sherkow JS; Greely HT
    Annu Rev Genet; 2015; 49():161-82. PubMed ID: 26442843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct to confusion: lessons learned from marketing BRCA testing.
    Matloff E; Caplan A
    Am J Bioeth; 2008 Jun; 8(6):5-8. PubMed ID: 18726769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Constructing narratives of heroism and villainy: case study of Myriad's BRACAnalysis(®) compared to Genentech's Herceptin(®).
    Baldwin AL; Cook-Deegan R
    Genome Med; 2013; 5(1):8. PubMed ID: 23369278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myriad Genetics: In the eye of the policy storm.
    Gold ER; Carbone J
    Genet Med; 2010 Apr; 12(4 Suppl):S39-70. PubMed ID: 20393310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Take off your genes and let the doctor have a look: why the Mayo and Myriad decisions have invalidated method claims for genetic diagnostic testing.
    Bergin C
    Am Univ Law Rev; 2013; 63(1):173-217. PubMed ID: 25335200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myriad and the mass media: the covering of a gene patent controversy.
    Caulfield T; Bubela T; Murdoch CJ
    Genet Med; 2007 Dec; 9(12):850-5. PubMed ID: 18091435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Business Ethics 101 for the biotech industry.
    MacDonald C
    BioDrugs; 2004; 18(2):71-7. PubMed ID: 15046523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MYRIAD AFTER
    Conley JM; Cook-Deegan R; Lázaro-Muñoz G
    N C J Law Technol; 2014 Jun; 15(4):597-637. PubMed ID: 25544836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The patent is political: the consequences of patenting the BRCA genes in Britain.
    Parthasarathy S
    Community Genet; 2005; 8(4):235-42. PubMed ID: 16244478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Architectures of genetic medicine: comparing genetic testing for breast cancer in the USA and the UK.
    Parthasarathy S
    Soc Stud Sci; 2005 Feb; 35(1):5-40. PubMed ID: 15991444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Opposition to Myriad Genetics patents and their total or partial revocation in Europe: early conclusions].
    Cassier M; Stoppa-Lyonnet D
    Med Sci (Paris); 2005; 21(6-7):658-62. PubMed ID: 15985212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Actor-network theory: a tool to support ethical analysis of commercial genetic testing.
    Williams-Jones B; Graham JE
    New Genet Soc; 2003 Dec; 22(3):271-96. PubMed ID: 15115034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human gene patents: the possible impacts on genetic services healthcare.
    Walpole IR; Dawkins HJ; Sinden PD; O'Leary PC
    Med J Aust; 2003 Aug; 179(4):203. PubMed ID: 12914511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Battle brewing over the BRCA1/2 gene patents.
    Agovic A
    Rev Derecho Genoma Hum; 2010; (33):171-94. PubMed ID: 21510137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The
    Sherkow JS; Cook-Deegan R; Greely HT
    Annu Rev Genomics Hum Genet; 2024 Feb; ():. PubMed ID: 38424474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2016; (43):9-61. PubMed ID: 27491172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efaproxiral: GSJ 61, JP 4, KDD 86, RS 4, RSR 13.
    Drugs R D; 2005; 6(3):178-85. PubMed ID: 15869322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. European opposition to exclusive control over predictive breast cancer testing and the inherent implications for U.S. patent law and public policy: a case study of the Myriad Genetics' BRCA patent controversy.
    Paradise J
    Food Drug Law J; 2004; 59(1):133-54. PubMed ID: 15190928
    [No Abstract]   [Full Text] [Related]  

  • 20. Guidelines, editors, pharma and the biological paradigm shift.
    Singh AR; Singh SA
    Mens Sana Monogr; 2007 Jan; 5(1):27-30. PubMed ID: 22058616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.